Real-world data and clinical management experience in passive immunization for respiratory syncytial virus prevention in children

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in children under 5 years of age worldwide. Currently, there are no approved curative treatments, and clinical management remains primarily focused on symptomatic support. As a result, preventive strategies are crucial for controlling RSV infections. Recent advancements have been made in the development of monoclonal antibody therapies aimed at protecting infants and young children from RSV. This review explores the application and real-world outcomes of passive immunization strategies in various international settings, particularly in developed countries, with a focus on their effectiveness and safety. The findings are intended to offer insights into the potential use of RSV passive immunization agents in developing countries.